Compare TG Therapeutics Inc (TGTX) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United Airlines Holdings Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while United Airlines Holdings Inc trades at $107.46 (market cap $34.87B). The key difference: United Airlines Holdings Inc is far larger — about 4.3× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and United Airlines Holdings Inc for 46 Days on average.
| TGTX | UAL | |
|---|---|---|
Market Cap | $8.16B | $34.87B |
Volume | 1,735,121 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $59.06 | $136.11 |
52-Week Low | $26.94 | $85.21 |
Typical Hold Time | 16 Days | 46 Days |
Enterprise Value | $8.37B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
United Airlines (UAL) trades at $107.44, down 2.48% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strength with a low P/E of 10.06, robust ROE of 23.25%, and consistent earnings beats in recent quarters. Recent news highlights aggressive customer acquisition efforts targeting Delta and American Airlines' premium flyers, leveraging Starlink WiFi partnerships to enhance its competitive edge.
The outlook is mixed: strong analyst consensus (66% buy ratings) and a $158.10 price target suggest upside, but rising fuel costs and bearish technicals pose near-term risks. Earnings sustainability and market share gains from strategic moves are key catalysts, while volatility in travel demand remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
